|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||34.15 - 34.76|
|52 Week Range||30.64 - 39.45|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||90.81|
|Earnings Date||Feb 1, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.31|
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio last week, listing four new positions. Warning! GuruFocus has detected 1 Warning Sign with ELAN. Managed by Jean Hynes, the fund invests in a number of diverse health care-related stocks from around the world in order to achieve long-term capital appreciation.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Qiagen (QGEN) delivered earnings and revenue surprises of 6.06% and -1.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Venlo, Netherlands-based company said it had profit of 26 cents. Earnings, adjusted for amortization costs and restructuring costs, were 35 cents per share. The results beat Wall ...
Sample to Insight solutions enabling deep analysis of disease-related genomic mutations
Adding QCI Analyze Universal to NGS bioinformatics offering, plus immuno-oncology content and additional features in analysis and interpretation
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New gastrointestinal panel includes comprehensive viral coverage and provides Sample to Insight workflows to clinics in Europe and Australia
QIAGEN N.V. plans as previously announced to release its report on results for the third quarter 2018 on Monday, October 29 shortly after 21:00 Central European Time / 16:00 Eastern Daylight Time .
Studies on new QIAGEN solutions for NGS are presented at ASHG as QIAseq portfolio and user base expands significantly
Frankfurt Prime Standard: QIA) today applauded a commitment by world leaders attending the first-ever high-level United Nations meeting on tuberculosis (TB) to mobilize $13 billion a year by 2022 to implement prevention and care for TB, the world’s most deadly infectious disease. The heads of state meeting at the United Nations General Assembly pledged to ensure that 40 million people who are diagnosed with tuberculosis receive the care they need by the end of 2022 and agreed to provide preventive testing and treatment to 30 million people.
Approval allows use of therascreen® EGFR RGQ PCR Kit as a companion diagnostic for Pfizer’s VIZIMPRO® in patients with non-small cell lung cancer
Mid-caps stocks, like QIAGEN NV (NYSE:QGEN) with a market capitalization of US$8.50b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Read More...